Jersey City, NJ, United States of America

Vikram Khetani

USPTO Granted Patents = 10 (Patent Applications = 7)

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 2.9

ph-index = 4

Forward Citations = 52(Granted Patents)

Location History:

Bridgewater, NJ (US) (1995)
Jersey City, NJ (US) (1999 - 2008)
Short Hills, NJ (US) (2006 - 2020)

Company Filing History:

The United States of America, As Represented by the Secretary, Department of Health and Human Services

patents

where one patent can have more than one assignee

Years Active: 1995-2020

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10682336 - PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS) (2020-06-16),

2. 10001483 - Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers (2018-06-19),

3. 7459560 - Processes and intermediates for resolving piperidyl acetamide stereoisomers (2008-12-02),

4. 7115631 - Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate (2006-10-03),

5. 6962997 - Process and intermediates for resolving piperidyl acetamide steroisomers (2005-11-08),

6. 6486177 - Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate (2002-11-26),

7. 6359139 - Methods for production of piperidyl acetamide stereoisomers (2002-03-19),

8. 5965734 - Processes and intermediates for preparing 2-substituted piperidine (1999-10-12),

9. 5936091 - Processes and intermediates for resolving piperidyl acetamide (1999-08-10),

10. 5468865 - Stereopreferential synthesis of (1995-11-21),

Title: Vikram Khetani: Innovator in Immunology

Introduction

Vikram Khetani, based in Jersey City, NJ, is a prominent inventor recognized for his significant contributions to the field of immunology. With a portfolio of 10 patents, Khetani focuses on advanced therapeutic methods to combat serious health conditions associated with immunodeficiency.

Latest Patents

Among his latest patents, Khetani has developed PDE4 modulators specifically designed for the treatment and prevention of immune reconstitution inflammatory syndrome (IRIS) in immunodeficient patients, particularly those with HIV. His innovative methods also extend to treating Kaposi's sarcoma and KSHV-induced lymphoma. The use of gene and protein biomarkers as predictors of clinical sensitivity offers a promising avenue for enhancing patient treatment outcomes with immunomodulatory compounds, either alone or in conjunction with doxorubicin.

Career Highlights

Khetani's career has been marked by his tenure at major pharmaceutical companies such as Celgene Corporation and Amgen Inc. These experiences have provided him with a solid foundation in drug development and therapeutic innovation, enabling him to design cutting-edge treatments that address critical health challenges.

Collaborations

Throughout his career, Khetani has collaborated with esteemed professionals in the field, including Jerome B. Zeldis and Sowmianarayanan Ramaswamy. These partnerships reflect a commitment to advancing medical research and improving patient care through innovative solutions in immunology.

Conclusion

Vikram Khetani stands out as an influential inventor whose work has the potential to improve the lives of patients suffering from severe immuno-related conditions. With his ongoing contributions and dedication to research, he continues to make significant strides in the field of medical innovation. His patented methods and collaborative efforts exemplify the power of innovation in driving progress in healthcare.

This text is generated by artificial intelligence and may not be accurate.